Exelixis Hires Three Veeps As Market Plans Loom for 2 medication
San Francisco Bay space biotech firm Exelixis (NASDAQ: EXEL) is bringing on board three new executives in anticipation of two drugs gaining FDA approval. the corporate, trying to flip around a foul run the past few years, as Xconomy wrote about in June, hired William Berg as senior VP of scientific affairs, Jonathan Berndt as VP of gross sales, and Gregg Bernier as VP of marketing.
Exelixis is ready to hear from the FDA whether or not cobimetinib can come to market as a part of a mix remedy for sufferers whose advanced melanoma is pushed by using a genetic mutation referred to as BRAF V600. a decision is due via November 11. The date was once at the beginning alleged to be August eleven, but the drug agency pushed it back this summer.
Exelixis additionally has in hand sure phase three study knowledge for every other drug, cabozantinib, in renal cell carcinoma, one of those kidney most cancers. The announcement of high-line knowledge in July bumped Exelixis shares from the $ three vary above $ 6 a share. it will present the full data set this weekend at the European most cancers Congress.
Exelixis owns full rights to cabozantinib, and it plans to post purposes to the FDA and European regulators for approval in coming months. the corporate had to retrench last 12 months when cabozantinib failed an incredible test in prostate cancer.
the company shares rights with cobimetinib with Roche’s Genentech unit, and it plans to participate in the sales and advertising efforts within the U.S.
(94)
